Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL598209 | 0.91 | MDM4 (0.56) | MDM4TP53CASP3MDM2 | |
| SCHEMBL29047045 | 0.91 | MDM4 (0.49) | MDM4TP53CASP3KMT2AEPHX2 | |
| SCHEMBL29355082 | 0.91 | MDM4 (0.56) | MDM4TP53CASP3MDM2 | |
| SCHEMBL29367497 | 0.91 | MDM4 (0.56) | MDM4TP53CASP3MDM2 | |
| SCHEMBL119575 | 0.91 | MDM4 (0.56) | MDM4TP53CASP3MDM2 | |
| SCHEMBL30802551 | 0.91 | MDM4 (0.56) | MDM4TP53CASP3MDM2 | |
| SCHEMBL119565 | 0.91 | MDM4 (0.56) | MDM4TP53CASP3MDM2 | |
| SCHEMBL29624621 | 0.91 | MDM4 (0.56) | MDM4TP53CASP3MDM2 | |
| SCHEMBL31385405 | 0.90 | MDM4 (0.47) | MDM4TP53CASP3KMT2AEPHX2 | |
| SCHEMBL6987530 | 0.90 | MDM4 (0.48) | MDM4TP53CASP3KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273768-B2 | Iso CA-4 and analogues thereof as potent cytotoxic agents inhibiting tubuline polymerization | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2012-09-25 | — | — | US | disclosed |
| US-8076285-B2 | Lysobactin amides | AICURIS GMBH & CO. KG (DE) | 2011-12-13 | — | — | US | disclosed |
| US-20090203582-A1 | LYSOBACTIN AMIDES | BAYER HEALTHCARE AG (DE) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203582-A1 | LYSOBACTIN AMIDES | AADAT, HAMP, DLST | MDM4 4264/4885TP53 4431/4885CASP3 2701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.